Recently, the International Association for the Study of Lung Cancer (IASLC) announced the results of its newly elected Council members to the world. Professor ZHOU Caicun of Shanghai Pulmonary Hospital affiliated with Tongji University was elected as the president-designate of the Council of IASLC from 2023 to 2025 and the president of the Council of IASLC from 2025 to 2027. This is the first time that an expert from the Chinese mainland was elected as the president of the IASLC since its establishment nearly 50 years ago.
Professor ZHOU Caicun was elected President-designate of the Council of the International Association for Lung Cancer Research
from 2023 to 2025 and Chairman of the Council from 2025 to 2027
Professor ZHOU Caicun is the chief physician, chief clinical expert, and doctoral supervisor of the Department of Oncology, Shanghai Pulmonary Hospital Affiliated with Tongji University. He is the director of the School of Medicine Oncology, Tongji University Medical School, the head of the key discipline of respiratory diseases in Shanghai, the chairman of the CSCO Non-small Cell Lung Cancer Committee, the chairman of Chest Cancer Branch of China Medical Promotion Association, and the leader of E-WEST. He won the Special Allowance from the State Council and is one of the leading talents in Shanghai. Long-term commitment to targeted therapy, anti-vascular therapy, immunotherapy, and clinical transformation of lung cancer. He has been responsible for or participated in more than 30 large-scale clinical studies, including OPTIMAL, BEYOND, and changed the guidelines for diagnosis and treatment of lung cancer in China. He has won a second prize in the National Science and Technology Progress Award, a first prize in the Shanghai Science and Technology Progress Award, and the IASLC Cancer Treatment Team Award (the only Asian team among the four winning teams in the world).
Since 2010, ZHOU Caicun has served as a member of the IASLC Education Committee, IASLC Tobacco Control Committee, and newsletter editor. In 2019, he became a core member (BOD) of the IASLC board of directors. After joining BOD, ZHOU Caicun devoted himself to IASLC preparing more educational conferences and regional seminars on all continents, organizing and carrying out global multi-center clinical trials and various forms of educational projects, to strengthen exchanges and cooperation among countries and regions around the world, and promote the development of medical education, scientific research and clinical practice.
IASLC is the only professional academic association dedicated to the study of lung cancer and other chest tumors in the world. It was established in 1974. At present, more than 8,000 lung cancer and chest oncologists from more than 100 countries/regions in the world have become members. IASLC is composed of the most authoritative and representative lung cancer experts from various countries/regions, with a term of four years.